Mergers & Acquisitions ·
Impact Biomedical Inc. announced that Zoar Limited filed a Form F-4 registration statement with the SEC on September…
IBOImpact Biomedical Inc.
Impact Biomedical Inc. announced that Zoar Limited filed a Form F-4 registration statement with the SEC on September 10, 2026, in connection with their previously announced business combination. The filing includes a preliminary proxy statement/prospectus for Impact shareholders to vote on the merger. Completion of the transaction is subject to SEC effectiveness of the Registration Statement, shareholder approval, and NYSE American listing approval. Upon closing, the combined entity will operate as a pharmaceutical company focused on developing and supplying active pharmaceutical ingredients and intermediates for special therapeutic treatment areas.